{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-177471","form_type":"8-K","ticker":"IOBTQ","cik":"0001865494","company_name":"IO Biotech, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.435356+00:00","generated_at":"2026-05-17T15:50:20.386245+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"IO Biotech Phase 3 Cylembio trial misses statistical significance; PFS improved 19.4 vs 11.0 mo","bullets":["Primary endpoint PFS HR=0.77 (CI 0.58-1.00), p=0.056, missed significance threshold p≤0.045.","Median PFS 19.4 months (Cylembio+pembrolizumab) vs 11.0 months (pembrolizumab alone).","PD-L1 negative subgroup median PFS 16.6 vs 3.0 months (HR 0.54, nominal p=0.006).","OS trend HR=0.79 (CI 0.57-1.10); company expects OS maturity in 6-9 months.","Estimated cash $28.1M as of June 30, plus €12.5M drawn July 4; runway into Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-177471","json":"https://secwatch.observer/filing/0001193125-25-177471.json","markdown":"https://secwatch.observer/filing/0001193125-25-177471.md","text":"https://secwatch.observer/filing/0001193125-25-177471.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1865494/000119312525177471/0001193125-25-177471-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1865494/000119312525177471/d454108d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:50:20.386245+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}